I listened to the call earlier today and was prepared to ask questions if the opportunity arose, but unfortunately, there was no open question opportunity.
I think the press release this morning is excellent, the design makes sense, I love the support from the NIH, and I especially like the comments coming from Dr. Alkon, Dr. Sabbagh, and Dr. Perry. If the most recent trial had an 80% probability of success (we got beat by a 4-1 shot!), this design sets up for an even higher probability of success as there is so much data that supports reasonably projecting success in this structure!
The call was disappointing, every statement was read and really didn't provide the extra insight I was hoping for. Dr. Ryan is not a great speaker and I "get" him reading his prepared comments, I think Dr. Alkon is so strong and credible when he speaks his thoughts contemporaneously, that I much prefer this to the prepared statements that he read.
For me, I want to make sense of and reconcile why there was an equity raise and dilution in late January 2020, that wasn't necessary and threw water on the very positive market reaction to the news released earlier that day; and then, a couple months later, that same cash and a little more was routed into an investment in an entirely different new company??? Somehow, this wasn't included in the "common questions they received from shareholders" that they read prepared answers to...
Market Data 
Markets 
AI
